98%
921
2 minutes
20
The transporter associated with antigen processing (TAP) translocates antigenic peptides into the endoplasmic reticulum (ER) lumen for loading onto MHC class I molecules. This is a key step in the control of viral infections through CD8+ T-cells. The herpes simplex virus type-1 encodes an 88 amino acid long species-specific TAP inhibitor, ICP47, that functions as a high affinity competitor for the peptide binding site on TAP. It has previously been suggested that the inhibitory function of ICP47 resides within the N-terminal region (residues 1-35). Here we show that mutation of the highly conserved PLL motif within the central region of ICP47 attenuates its inhibitory capacity. Taking advantage of the human cytomegalovirus-encoded TAP inhibitor US6 as a luminal sensor for conformational changes of TAP, we demonstrated that the PLL motif is essential for freezing of the TAP conformation. Moreover, hierarchical functional interaction sites on TAP dependent on PLL could be defined using a comprehensive set of human-rat TAP chimeras. This data broadens our understanding of the molecular mechanism underpinning TAP inhibition by ICP47, to include the PLL sequence as a stabilizer that tethers the TAP-ICP47 complex in an inward-facing conformation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462769 | PMC |
http://dx.doi.org/10.1038/s41598-017-02994-5 | DOI Listing |
J Immunother Cancer
September 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Response to immune checkpoint inhibition (ICI) in sarcomas is overall low and heterogeneous. Understanding determinants of ICI outcomes may improve efficacy and patient selection. Thus, we investigated whether the expression of transposable elements (TEs), which are epigenetically silenced and can stimulate antitumor immunity, influence ICI outcomes and immune infiltrates in common sarcoma subtypes.
View Article and Find Full Text PDFCancer Treat Rev
August 2025
Icelandic Medicines Agency, Iceland.
Ultra-rare sarcomas (URS) and ultra-rare cancers (URC) represent a unique challenge in oncology due to their rarity, heterogeneity, and the severe unmet clinical needs of affected patients. In 2024, the European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) convened two multi-stakeholder workshops, bringing together regulators, clinicians, researchers, and patient advocates. These workshops aimed to explore innovative strategies for treatment development and establish a framework for future collaboration.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
August 2025
Department of Medicine, University Medical Center of Johannes Gutenberg University, Mainz, Germany. Electronic address:
Background: Advanced esophageal cell carcinoma (ESCC) is associated with poor survival outcomes. PD-1/PD-L1 inhibitors have been approved for the treatment of advanced ESCC. We aim to study PD-1/PD-L1 inhibitors across other variables in advanced ESCC, including data presented at the September 2024 FDA Oncologic Drugs Advisory Committee (ODAC) meeting.
View Article and Find Full Text PDFTalanta
July 2025
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address:
A novel carbon-based nanozyme has been designed and synthesized via upcycling expired pharmaceutical; gabapentin (GABA) into Fe, N, S-doped carbon dots within 3 min of microwave irradiation. The engineered nanozyme exhibits unique dual oxidase/peroxidase-mimicking activities. Thus, a dual-mode sensing microplate-based platform was introduced.
View Article and Find Full Text PDFESMO Open
August 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA.
Background: Sarcomas are frequently infiltrated with immunosuppressive myeloid cells. Vimseltinib is an inhibitor of the colony-stimulating factor 1 receptor kinase and has been shown to decrease tumor-infiltrating myeloid cells in preclinical models. We hypothesized that vimseltinib combined with the Programmed death-ligand 1 (PD-L1) inhibitor avelumab would be safe, tolerable, and clinically effective in patients with advanced sarcoma.
View Article and Find Full Text PDF